10.1177/2040622315579059 Ther
Pregnant or breastfeeding women should consult their doctor or health care practitioner
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
doi: 10.1046/j.1365-2036.2000.00837.x 46 BugdaciMSZuhurSSSokmenMToksoyBBayraktarBAltuntasY
ROS-mediated DNA injury compromises satellite cell regenerative capacity, while oxidized macromolecules accumulate within atrophic fibers (Nakazzi et al., 2025)
MILD does not work for every type of spinal stenosis it is specifically designed for ligament-driven stenosis
